OXIHUMIC ACID AND ITS USE IN THE TREATMENT OF VARIOUS CONDITIONS

Abstract: A pharmaceutical composition comprising an oxihumic acid, salt, ester or derivative thereof as an active ingredient is disclosed. The composition is preferably administered orally for stimulating lymphocytes in a human, animal or bird. It may be used in treating viral and bacterial infections, HIV infections, opportunistic diseases, inflammation, pain and fever, cancer growth and diseases associated with viral infection and a depressed immune system.

Description: OXIHUMIC ACID AND ITS USE IN THE TREATMENT OF VARIOUS CONDITIONS BACKGROUND OF THE INVENTION This invention relates to oxihumic acid and its use in the treatment of various conditions. Humic acids are formed during the decomposition of organic matter and can therefore be found in practically all natural environments in which organic materials and microorganisms are, or have been present (Visser, 1973). Humic acids have been used in medicines at a dosage of between 0.9 and 1.8g daily for the treatment of hyperacidity and other gastric disturbances in humans (Gramsch,1961 ; Reichert, 1966). No unfavourable side effects have been observed at the above-mentioned doses. Humic acids have also been successfully used as anti-inflammatory agents because of their local anti-inflammatory, hyperaemic and analgesic properties (Salz, 1974; Motohisa et al. , 1974) and as a systemic treatment for anaemia and hypercholesterolaemia (Soloveyva and Lotosh. 1984). Peat extracts have been used in therapeutic baths for the treatment of various conditions for many years (Brandt, 1964; Eichelsdorfer, 1976). The antiseptic properties of peat were first recognised during World War 1 when it was applied directly on to battle wounds to prevent infection (Haanel, 1924). The possible application of coal-derived humic acid and fulvic acid as antimicrobials, has recently been investigated by Cloete et al. (1990) of the Department of Microbiology, University of Pretoria. More recently, humate has been used in the treatment of Von Willebrand disease (Lopez-Fernandez et al. , 1992). Patients were treated with an infusion of 35 mg/kg body weight after which normal VIII levels were achieved. It has been reported that humic acids derived from either the decomposition of organic matter (Sato et al. , 1986) or the oxidation of coal (Bernacchi et al. , 1996) do not act as mutagens, but interestingly, may rather on the other hand behave as desmutagens (Takahiko et al. , 1986) by inhibiting the mutagenicities of selected mutagens. The anti-tumour properties of humic acids were first investigated in vivo by Zsindely et al. (1971) who reported that mice which received 10-40 mg humic acids orally for 5 days after experimental induction of cancer by administration of ascites sarcoma or lymphoma (IP) showed a greatly reduced tumour load 10 days later. They also found that the humic acid treatment resulted in a 20 - 25 % decrease in the RNA and DNA content of tumour cells. Humic acids have also been shown to control uterine cancer in rats (Davies, 1996). Since they are highly surface-active (Visser, 1982), these acids may act on the membranes of malignant cells, which often differ in structure and function of normal cells (Bennet & Connon, 1957). Adamek (1976) reported that a peat preparation administered orally, rectally or intramuscularly at tumour sites resulted in their arrest or regression. Antiviral properties, at a concentration of lOOμg/ml of ammonium humate in vitro have been described by Thiel et al. (1981) resulting in the successful use of this agent as a topical treatment for herpes virus-induced skin diseases (Klocking et al. , 1983). Schneider et al. (1996) reported on the anti-HIV activity of synthetic humate analogues derived from hydroquinone. These compounds inhibited HIV-1 infection of MT-2 cells with an impressively low IC™ of 50-300 ng/ml. The infectivity of HIV particles was inhibited by interference with the CD4-induced proteolytic cleavage of the V3-loop of virion gpl20SU. SUMMARY OF THE INVENTION According to a first aspect of the invention, there is provided a humic acid, salt, ester or derivative thereof, for use in the manufacture of a medicament for use in stimulating lymphocytes in a subject. According to a preferred form of the invention, there is provided the use of a humic acid, salt, ester or derivative thereof, in the manufacture of a medicament for use in stimulating the THI and TH2 lymphocytes in a subject. Stimulation of the THI and TH2 lymphocytes in a subject allows the medicament to be used, for example, in the treatment of viral and bacterial infections, and more particularly HIV infections, cancer and opportunistic diseases. The invention provides, according to a particularly preferred aspect, a medicament of the type described above for oral administration. It has been found that the humic acid, salt, ester or derivative thereof is rapidly taken up by the subject if administered orally. The invention further provides a method of stimulating lymphocytes in a subject which includes the steps of administering a humic acid, salt, ester or derivative thereof, to the subject. The amount of humic acid, salt, ester or derivative thereof, administered to the subject will be effective to stimulate lymphocytes in the subject. The subject may be a human, animal or bird. Examples of specific uses of the humic acid, salt, ester or derivative thereof are inhibiting viral and bacterial infections, inhibiting cancer growth, the treatment of myalgic encephalitis (ME) associated with viral infections and a depressed immune system, inflammation, pain and fever. The active ingredient in the practice of the invention is humic acid, a salt, ester or derivative thereof. Humic acid is a complex mixture of macromolecular organic substances which are not soluble in water under acidic conditions, i.e. at pH below 2, but are soluble at higher pH values. The invention has particular application to a humic acid which may be produced, for example, by the wet oxidation process described in US patent 4,912,256. Such humic acid is hereinafter referred to as "oxihumic acid". The potassium or sodium salt of a humic acid, particularly oxihumic acid, may be produced by the method described in US patent 5,004,831. Oxihumic acid also has no defined structure. It is a complex mixture of organic compounds. It is acidic in nature, due to its carboxylic and phenolic groups. Oxihumic acid is practically insoluble at low pH in water, but becomes soluble in alkaline aqueous medium. Oxihumic acid can, therefore, be regarded as a relatively high molecular mass product containing carboxylic and phenolic groups. Oxihumic acid compared to so-called natural humic acids has a relatively high degree of aromaticity. A typical functional group analysis of oxihumic acid is given below: Total acid groups: 3 - 13 meq/g, preferably 5.4 meq/g Carboxylic groups: 0.5-12 meq/g, preferably 2.2 meq/g Phenolic groups: 0.5 - 9 meq/g, preferably 3.2 meq/g The humic acid, salt, ester or derivative thereof will preferably be provided in a pharmaceutical composition form suitable for oral administration. A particularly suitable form is a capsule. The active ingredient may be present in the capsule with or without excipients. The invention provides, according to yet another aspect, a pharmaceutical composition comprising oxihumic acid, salt, ester or derivative thereof, as an active ingredient. The composition has particular application in the treatment and the control of viral infections such as HIV infections, and cancer. For these applications, the composition is preferably administered orally. BRIEF DESCRIPTION OF THE DRAWINGS Figures 1 to 30 illustrate graphically the results of certain tests carried out on potassium oxihumate and humic acid. DESCRIPTION OF EMBODIMENTS Potassium oxihumate, having the preferred functional group analysis mentioned above and hereinafter referred to as "oxihumate", has been subjected to a number of in vitro and in vivo studies and these are described hereinafter. i) Effects of oxihumate on the proliferative responses of phytohaemagglutinin (PHA)-stimulated human lymphocytes. In these experiments suspensions of purified human monocyte depleted lymphocytes, at a concentration of 1 x 10 6 lymphocytes/ml in RPMI medium supplemented with 10% fetal calf serum (FCS), were added to the wells of microtitre plates. To some of the wells a mitogen (phytohaemagglutinin, PHA) was added at a concentration of 2.5 μg/ml. The cultures were incubated either with or without oxihumate (5 - lOOμg/ml) for 72h at 37°C in an atmosphere of 5% CO2. The extent of lymphocyte proliferation was assayed by MTT [3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide] reactivity which detects only viable cells. Oxihumate had no effect on resting lymphocytes but increased the proliferative response of PHA-stimulated lymphocytes in a dose-related manner (Figure 1). Similar results were obtained with a synthetic humic acid (Sigma Chemicals Co. , St. Louis, Mo). Oxihumate was on average more effective at 80 and 100 μg/ml than the synthetic humic acid (Figure 2) . Effects of oxihumate on the expression of the activation markers CD25 and CD38 on human lymphocytes. Resting or PHA-stimulated human lymphocytes were incubated in test tubes at a concentration of 1 x 10 6 cells/ml in RPMI medium supplemented with 10% FCS for 72 h in either the presence or absence of oxihumate (lOOμg/ml) and the expression of the IL-2-receptor (CD25) and CD38 (a molecule involved in signal transduction and cellular adhesion), was analysed using a flow cytometer (Coulter Epics XL-MCL). It was observed that oxihumate had no effect on the expression of either CD25 or CD38 on resting lymphocytes (results not shown), but increased the expression of CD25 significantly on PHA-stimulated cells, whereas the expression of CD38 on these cells decreased with oxihumate treatment (Figure 3). iii) Interleukin 2 (IL-2), interleukin 4 (IL-4) and interleukin 6 (IL-6) production by human lymphocytes. PHA-stimulated human lymphocyte cultures were treated as above with oxihumate at 60, 80 and 100 μg/ml for 48 h, whereafter the cells were centrifuged and the cell-free supernatants assayed for IL-2, IL-4 or IL-6 levels, using a Biotrak TM human ELISA system from Amersham TM (Amersham International Pic, Buckinghamshire, England). Results obtained from 4 different experiments are shown in Figures 4 to 6. Oxihumate caused a statistically significant increase in IL-2 and IL-4 production by stimulated lymphocytes at all three concentrations tested (Figures 4 and 5). A slight but not significant increase in IL-6 production by oxihumate was also observed (Figure 6). iv) Increased antibody production against Newcastle disease in chickens treated with oxihumate In an experiment to determine the efficacy of oxihumate to control Mycoplasma gallisepticum infection in Ross 308 broiler chickens, 2550 day- old chickens were divided into 5 groups, infected with the organism and treated as follows: Treatment 1 : control, untreated Treatments 2-4: 50, 100 or 200mg oxihumate/kg/day Treatment 5: Baytril, lOmg/kg/day for 3 days in the first week of life, followed by a one day treatment at 21 days of age All chickens were vaccinated at 16 days of age for Newcastle disease and Gumboro to establish the effect oxihumate has on the production of antibodies against these diseases in chickens. Blood samples of 15 birds per treatment were taken at 28 days and 45 birds per treatment at 42 days to determine antibody titers against Newcastle and Gumboro diseases using the ELISA test system. No difference in antibody titers against Gumboro between the treatment and control groups was found (results not shown). However both the Baytril treatment group and the group treated with lOOmg oxihumate/kg/day showed a two to four fold increase in titers against Newcastle disease at day 28 and 42 (Figure 7) indicating the ability of these two compounds to stimulate the humoral immune response. Results on the presence of M . gallisepticum in the treated and control groups are not yet available. An increase in IL-2, necessary for cell-mediated (Ttil-type) immunity, as well as an increase in IL-4 and IL-6, necessary for humoral (TH2-type) immunity, indicate that this compound can be an effective immunostimulant which may prove suitable for application by patients suffering from viral and bacterial infections. Interleukin 10 (IL-10) production by oxihumate treated lymphocytes. PHA-stimulated human lymphocyte cultures were treated with oxihumate at 60, 80 and 100 μg/ml for 48 h, whereafter the cells were centrifuged and the cell-free supernatants assayed for IL-10 levels, using Biotrak high sensitivity IL-10 ELISA system from Amersham TM (Amersham International Pic, Buckinghamshire, England). The results obtained from 3 different experiments are shown in Figure 8. Oxihumate inhibited IL-10 production by PHA-stimulated lymphocytes at all three concentrations tested. These results confirm the IL-2 results indicating an increase in Tnl cell activity. Leukotriene B4 (LTB4) production by oxihumate treated lymphocytes Phorbol 12-myristate 13 -acetate (PMA, at 100ng/ml)-stimulated human lymphocyte cultures (1 X 10 6 lymphocytes / ml in RPMI medium supplemented with 10% FCS) were treated with oxihumate at 60, 80 and lOOμg/ml for 20 min at 37°C. The cultures were centrifuged and the supernatants assayed for LTB4 levels, using Biotrak LTB4 enzyme immuno- assay system from Amersham International Pic, Buckinghamshire, England. The results obtained from 4 different experiments are shown in Figure 9. Oxihumate increased LTB4 production by PMA-stimulated human lymphocytes more than 300% compared to the untreated controls at all 3 concentrations tested (Figure 9B). The role of leukotrienes in the immune response is less clear. Various researchers have reported that LTB4 can act as a multifunctional regulator of cytokine production and that it is able to stimulate both Tnl and TH2 subpopulations. LTB4 not only plays an important role in the induction of the production of IL-2 but also enhances the activity of cytotoxic T-cells and this could possibly explain the increase in IL-2 production as well as the increase in cytotoxicity of oxihumate-treated lymphocyte cultures. vii) Prostaglandin E2 (PGE2) production by oxihumate treated lymphocytes Phorbol 12-myristate 13-acetate (PMA, at 100ng/ml)-stimulated human lymphocyte cultures (1 X 10 6 lymphocytes / ml in RPMI medium supplemented with 10% FCS) were treated with oxihumate at 60, 80 and lOOμg/ml for 20 min at 37°C. The cultures were centrifuged and the supernatants assayed for PGE2 levels, using Biotrak PGE2 enzyme immuno- assay system from Amersham International Pic, Buckinghamshire, England. The results obtained from 8 different experiments are shown in Figure 10. Oxihumate decreased PGE2 production by PMA-stimulated human lymphocytes by between 20 and 30% compared with the untreated controls at all 3 concentrations tested (Figure 10B). PGE2 is recognized for its capacity to induce pain and fever. It inhibits T cell proliferation by down-regulating TH I -associated cytokine (IFN-λ, TNF-β and IL-2) production. Although oxihumate (up to lOOμg/ml) mediated inhibition of PGE2 production did not exceed 30% of control values, a decreased level may contribute to an increase in lymphocyte proliferation and THI -associated cytokines. viii) Tumor necrosis factor (TNF) production by oxihumate treated lymphocytes PHA stimulated human lymphocytes were treated with oxihumate at 10, 20, 40, 60, 80 and lOOμg/ml for 24h at 37 °C and the supernatants assayed for TNF levels, using Biotrak TNF-α enzyme immuno-assay system from Amersham International Pic, Buckinghamshire, England. Oxihumate decreased the production of TNF by PHA-stimulated human lymphocytes significantly at concentrations of 10, 20 and 40μg/ml compared to the untreated control (Figure 11). TNF plays an important role in inflammation and acts on endothelium, leukocytes and fibroblasts especially in the induction of the systemic acute- phase reactions associated with infection or injury. It induces the synthesis of endothelial adhesion molecules, other cytokines, growth factors and nitric oxides. TNF also causes aggregation and the priming of neutrophils, leading to augmented responses of these cells to other mediators and the release of proteolytic enzymes from mesenchemal cells, thus contributing to tissue damage. A decreased production of TNF would therefore lead to a favourable reaction during both acute as well as chronic inflammatory conditions. ix) Expression of CR3 by oxihumate treated polymorphonuclear leukocytes Human leukocytes were treated with oxihumate (10-100ug/ml) for 30 min in RPMI supplemented with 10% fetal calf serum in the presence or absence of phorbol myristate acetate (PMA), and assayed for the expression of CR3 on the cell membranes of polymorphonuclear leukocytes (PMNL) using a flow cytometer (Coulter Epics XL-MCL). Oxihumate decreases the expression of CR3 on PMA-stimulated. but not resting, PMNL significantly in a dose related fashion at all 6 concentrations tested (Figure 12). This property is shared by various new and effective anti- inflammatory drugs such as theophylline and ibudilast. More over anti-CR3 monoconal antibodies have been used successfully in the treatment of induced inflammation disorders in experimental animals. CR3 is a member of a family of leukocyte proteins that mediates adhesion in a variety of cell to cell and cell to substrate interactions. It plays a crucial role in phagocytosis, diapedesis and the movement of leukocytes through an endothelial monolayer into tissues. Adhesion molecules therefore play a key role in inflammatory processes present in diseases such as autoimmune diseases as well as allergic reactions. Inhibition of the expression of adhesion molecules such as CR3 by oxihumate should make it an effective drug in the treatment of inflammatory diseases. Cytotoxic activity of oxihumate-treated human lymphocytes PLC cells (a human liver cancer cell line), (5 x lOVml) were cultured in RPMI medium supplemented with 10% FCS for 72 h in 96 well round -bottom microtitre plates either in the presence or absence of human lymphocytes (1:2 ratio for target cells lymphocytes). These cultures were treated with oxihumate (5-100 μg/ml) for 72 h, after which the lymphocytes were removed by washing and the mitochondrial activity of the adherent PLC cells determined using a standard MTT assay. Oxihumate inhibited the growth of PLC cells at concentrations of 10 μg/ml and higher (Figure 13). The addition of human lymphocytes to the system significantly increased the level of inhibition (Figure 13). Antiviral activity of oxihumate against herpes simplex virus type 1 (HSV-1) and coxsackie virus type 1 (CBV-1) in vitro To investigate the effect of oxihumate on the replication of each virus. 42h old monolayers of vervet monkey kidney (VK) cells were infected with either HSV- 1 or CBV-1. After one hour the unbound virus was removed and the cells treated with various concentrations of oxihumate in serum-free MEM (minimum Eagles' medium) at 37°C in a humidified CO2 atmosphere for 7 days. To investigate the effect of oxihumate on viral absorption to cells oxihumate and the virus suspension were added simultaneously to the cell cultures and incubated at 37°C in a humidified CO2 atmosphere for 7 days. To investigate the effect of oxihumate on the infectivity of viral particles, equal volumes of viral suspensions were mixed with dilutions of oxihumate and incubated for one hour at 37°C. The oxihumate/ virus suspension was added to a 24h culture and incubated at 37 σ C in a humidified CO2 atmosphere for 7 days. The appearance of a cytopathic effect (CPE) was considered to be indicative of a lack of inhibition of viral replication. The percentage CPE reported is the mean of the percentage CPE noted in each of the 6 experimental wells. In all three methods cells were examined by light microscopy daily for 7 days. Oxihumate (3.9-1000μg/ml) had no effect on the adsoφtion and/or replication of CBV-1 (results not shown). In contrast to this, marked anti-viral activity against HSV-1 was noted at concentrations of 62.5 to 250μg/ml (Figures 14 and 15). Because the virus was more sensitive when added simultaneously with the compounds to the cells (Figure 15). the data therefore suggests that oxihumate interferes with the adsorption to and subsequent replication of HSV- 1 in cell culture. When the infectivity on both CBV-1 and HSV-1 were assessed after exposure to the different concentrations of oxihumate for one hour at 37°C a total inhibition of infectivity of HSV-1 as well as CBV-1 was noted at concentrations of 62.5-500μg/ml and 125-500μg/ml respectively. (Table 1). TABLE 1 Dose response of Coxsackie B virus type 1 on vervet monkey kidney cells after exposure to oxihumate at 37°C for 1 hour The percentage CPE reported is the mean of the percentage CPE noted in each of the 4 experimental wells. xii) Antiviral activity of oxihumate against HIV-1 in vitro To investigate the effect of oxihumate on the replication of HIV-1 IIIB laboratory strain, a suspension of the virus (HIV-1) was added to oxihumate concentrations between 0.35 and 200μg/ml for 15 min at room temperature prior to the addition of MT-2 cells (a CD4 positive human lymphocyte cell line). The cell cultures were incubated at 37°C in a humidified CO2 atmosphere for 5 days after which syncytia formation was determined by light microscopy. The results of three experiments done in triplicate can be seen in Figure 16. A 50% inhibition of viral growth was observed at an oxihumate concentration of 16μg/ml. These results were confirmed by a different research group using the same (HIV-1 IIIB laboratory strain) and a different (HIV-1 D) isolate of HIV-1 (Figures 17 and 18). In these cases the activity of oxihumate was compared to that of AZT. Oxihumate at 25 μg/ml reduced viral growth in both cases to the same level as 0.3μM and 12.5 μM AZT. Although inhibition of HIV-1 in cell cultures by a synthetic humate analogue has been described by Schneider et al 1996, these results are the first to document the anti-HIV-1 activity of oxihumate. (xiii) Phase I Clinical Trial of oral oxihumate in HIV-infected patients HIV-infected patients have been treated with either 2 g, 4 g or 6 g oxihumate per day for two weeks. Nine patients were randomized in a double-blind fashion in each group into 2 arms: one arm in which 7 patients were on oxihumate at a dose of either 2 g, 4 g or 6 g per day and another arm with 2 patients on placebo. The patients were treated for 2 weeks and followed-up two weeks after completion of treatment. Clinical evaluation: None of the patients had previous AIDS-defining events and no such events took place during the study. All of the patients suffered from previous HIV- related infections, but two weeks of treatment was too short a period to reach any meaningful conclusions. There was a significant increase in the weight of the patients on all three dosages of oxihumate compared to the placebo controls during the study period (Figure 19). Most of the oxihumate-treated patients reported a significant improvement in energy levels. The patients did not experience any gastrointestinal side-effects such as nausea and vomiting while on treatment. Most of the patients reported increased appetite. Toxicity There was no change in electrolytes (Figure 20) or glucose (Figure 21). No toxicity regarding liver (Figure 22) and kidney (Figure 23) function was observed. Haemoglobin levels (Figure 24) and platelet counts (Figure 25) remained stable. The absolute neutrophil count (Figure 26) did, in some cases (2 g/day), increase without any sign of infection being the cause, although the rise was not significant. Viral load and CD 4 counts No significant changes in the viral load (Figure 27), the absolute lymphocyte count (Figure 28) and the CD 4 count (Figure 29) were noted. Conclusion On a dosage of 2 g, 4 g and 6 g oxihumate per day for two weeks there was no obvious toxicity, while no significant changes in any of the markers reflecting the function of the immune system were noted. Effects of a 2-week treatment of HIV-positive patients with oxihumate (at 4 g and 6 g a day) on the proliferative response of phytohaemagglutinin (PHA)(5 mg/ml)-stimulated human lymphocytes. Oxihumate treatment in vivo increased the proliferative response in vitro of PHA-stimulated lymphocytes (Figure 30). xiv) Pharmacokinetics The pharmacokinetics of l2 I-oxihumate in the baboon was studied by Prof I Dormehl at the Atomic Energy Corporation Institute for Life Sciences (Table 2). Eight baboons were fasted for 24 hours. Four received a mixture of cold and 123 I-labelled oxihumate (55 mg/kg) via a stomach tube directly into the stomach and four received the substance endoscopically directly into the duodenum. Scans were performed and urine and blood samples were taken regularly. The results of these investigations are shown in Table 2. Rapid systemic uptake of oxihumate was seen within 30 min. , occurring faster in the duodenum than in the stomach. The labelled substance appeared in the cardiac bloodpool at 30 min and a maximum of 11.7% of the activity remains at 23 hours. The target organs of 123 I-oxihumate accumulation were the gastrointestinal tract, liver, kidneys, mucosa and lymphocytes and excretion was via the bowel and kidneys. No side effects were detected during the study. TABLE 2 The pharmacokinetics of oxihumic acid labelled with 123 I measured as percentage of remaining injected dose in each compartment % Urinary output (of injected dose) 1 - 4 hr: 5.71 ± 0.62% 1 - 5 hr 12.8 hr ± 3.7% 18 - 23 hr 21.43 % 23- 28 hr 9.9 ± 2.4% (xv) Toxicity studies in animals Oxihumate has been tested extensively for toxicity in experimental animals (Table 3). Details of the tests and the results thereof are set out hereinafter. Further, oxihumate did not produce any measurable toxicity during either acute and sub-chronic oral and dermal exposure. TABLE 3 Toxicity studies on oxihumate STUDY TYPE OF STUDY RESULTS NUMBER 1503 Acute oral toxicity in rats LD50 value > 3456 mg/kg 1504 Acute dermal toxicity in rats LD50 value > 4147mg/kg 1505 Acute dermal irritation Non-irritant 1506 Acute eye irritation Mild irritant 1507 Skin sensitization Weak skin sensitizer 1511 Subchronic oral toxicity in rats Highest dose tested was 1000 (90-day study) mg/kg/day. No deaths or sick animals. Slight alterations in blood chemistry and slight decreases in body masses. 1557 Subchronic dermal toxicity in rats Highest dose tested was 1000 (90-day study) mg/kg/day (of the active substance). No deaths or sick animals. Slight alterations in blood chemistry and slight decreases in body masses. 1633 Subchronic oral toxicity in dogs (90 Highest dose tested was 1200 day study) mg/kg/day. No deaths or sick animals. Slight alterations in blood chemistry and slight decrease in body masses. 1639 Combined chronic toxicity / The chronic toxicity study has been carcinogenicity study completed. A progress report at the 12 month stage stated that no abnormal clinical signs were observed and none of the animals died or showed any signs of cancer. DISCUSSION OF RESULTS Study 1503: Acute oral toxicity in rats. The oral LD50 value is estimated to be greater than 3456 mg/kg. Thus, the active ingredient can be classified as practically non-toxic for humans. Study 1504: Acute dermal toxicity study in rats. The dermal LD50 value to be greater than 4147 mg/kg. Study 1505: Acute dermal irritation/corrosion test in rabbits. The evaluation of the Primary Irritation Index (PPI), was made according to both EPA and EEC criteria. No oedema, erythema or notable dermal lesions were observed during the study. According to EEC criteria oxihumate is classified as a non-irritant for erythema and oedema. Similarly, according to EPA criteria the potassium oxihumate is classified as a non-irritant. Study 1506: Acute eye irritation/corrosion test in rabbits. Under the conditions of this study the oxihumate is considered to be a mild irritant to the ocular tissue of the rabbit. According to the EEC Ocular Evaluation Criteria the humate is considered to be non-irritant to the cornea, non-irritant for iris lesion, non- irritant for conjunctival redness and non-irritant for conjunctival oedema. Study 1507:Contact hypersensitivity in albino guinea pigs (Magnusson Kligman Maximization test). No oedema or erythema was observed in any of the animals during the observation period. It can therefore be concluded that the pure test item did not provoke skin sensitization in the animals. It is therefore classified as having a weak sensitization potential according to the Magnusson Kligman Maximization criteria. Study 1511: Subchronic oral toxicity - rodent: 90 day study with potassium oxihumate. "None of the animals died during the 90 day study period as a result of the test substance. There were no notable differences between the pathology and organ masses of animals receiving the test substance, compared to the control animals. No abnormal clinical signs were observed in animals receiving the test substance. The only notable changes were the consistent increase in serum globulins as well as a drug-related increase in the size and haemoglobinization of the red blood cells of treated animals. There were also a decrease in serum inorganic phosphate and a decline in circulating lymphocytes. The observed effects were principally evident in female rats. There was a statistically significant decrease in end body mass of male treated animals of the two high-dose groups. The end body masses of these two groups were, however, still within the reference range for animals of that age group. The observations of the blood chemistry do not necessarily indicate deleterious effects, and might even signify beneficial properties, which should be further researched. Animals in the high-dose group received oxihumate at a dose rate of 1000 mg/kg/day over a 90-day study period. Taking into account the high dose rate, it can be assumed that oxihumate is practically non-toxic over this exposure period at this specific dose. Study 1557: Subchronic dermal toxicity - rodent: 90 day limit study with potassium oxihumate. Animals received potassium oxihumate at a dose rate of 1000 mg/kg/day over a 90- day period. None of the animals showed any abnormal clinical signs or died during the 90-day study period. There were no differences between the measured pathology, body masses and organ masses of animals receiving the test substance compared to the control animals. The test substance altered some of the chemical pathology parameters. The results were, however, not consistent. The results suggest a very low grade acid-base disturbance. The test substance, at the dose used and in the manner applied, does not appear to have any serious deleterious effect on the experimental animals as indicated by the parameters assessed. Study 1633: Potassium oxihumate sub-chronic oral toxicity study in dogs. The test substance, even at 1200 mg/kg/day, did not induce marked clinical signs of toxicity. During the whole study period, all the animals displayed normal physical appearances and behaviour patterns. The clinical pathological data showed that the test substance had some, but usually small, effects on the measured parameters. Most of the changes were not consistently dose-related and probably not of clinical significance. Many of the changes were to be expected with ageing animals. All animals were euthanased after the 90-day period and a comprehensive post mortem examination as well as a histopathological evaluation of an extensive list of organs were performed. This investigation showed that the test substance did not induce any measurable pathology at the macroscopic and microscopic level. This finding correlates with the clinical pathological investigation. Oxihumate appears to be a substance of low toxicity in the manner and dose applied. The results of this study were comparable with the rodent sub-chronic toxicity study. Study 1639: Combined chronic toxicity /carcinogenicity study. (Progress report at the twelve month stage). For the first twelve months of both studies, no abnormal signs were observed in any of the animals dosed with the test substance. None of the animals have died as a result of the test substance and none of the animals are showing any sign of cancer at this stage. Oxihumate is therefore a compound that: i) increases lymphocyte proliferation. This property is shared by synthetic humic acids; ii) exhibits antiviral activity against enveloped viruses, such as HIV-1 and HSV-1; iii) increases IL-2 production by stimulated lymphocytes in vitro, a cytokine that might rescue the steadily declining CD 4 lymphocyte population in HIV- infected patients; iv) increases IL-4 and IL-6 production by stimulated lymphocytes in vitro, cytokines associated with humoral immunity; v) increases antibody production against Newcastle disease in chickens; vi) inhibits the secretion of IL-10 by stimulated lymphocytes in vitro, a cytokine associated with a decrease in IL-2 production; vii) increases the cytotoxic activity of both resting and PHA-stimulated lymphocytes, using a human liver cancer cell as the target; viii) increases both THI and TH2 lymphocyte activity in vitro, important host defence mechanisms operative against viral and bacterial infections; ix) increases secretion of LTB4 by stimulated lymphocytes, a compound associated with an increase in the production of cytokines associated with both THI and TH2 as well as enhanced cytotoxic activity of lymphocytes; x) decreases PGE2 secretion by stimulated lymphocytes, a compound associated with inflammation, pain and fever; xi) decreases secretion of TNF by stimulated lymphocytes, a compound associated with inflammation; xii) inhibits expression of adhesion molecules such as CR3 on cell surfaces; xiii) decreases CD38 levels in vitro, a strong negative prognostic marker in HIV- infected individuals; xiv) is taken up rapidly and appears in the serum within 30 minutes; xv) has very low toxicity in experimental animals; xvi) is non-toxic up to a dosage of 6 g per day in HIV-infected individuals; xvii) increases the lymphoproliferative response and weight of HIV-infected individuals after two weeks. REFERENCES Adamek W. Introductory report on oncostatic and therapeutic nature of the peat preparation in human neoplastic disease. In: Peat and Peatlands in the Natural Envirnoment Protection. Proc 5 th Int Congress, Poznam, Poland 1976;1:417-429. Aspinal S, Bos P, Alexander JJ. Oral administration of Efamol G to nude mice bearing human hepatocellular carcinoma zenografts. S A J Science 1988;84:852-854. Bennet LR, Connon FE. Effects of lytic agents on plasma membranes of Ehrlich ascites-tumor cells and mouse erythrocytes. J Nat Cancer Inst 1957; 19:999-1011. Bergh JJ, Cronje IJ, Dekker J, Dekker TG, Gerritsma LM, Mienie LJ. Non-catalytic oxidation of water-slurried coal with oxygen: identification of fulvic acids and acute toxicity. Fuel 1997;76: 149-154. Bernacchi F, Ponzanelli 1 , Barale R, Loprieno N. Mutagenic activity of coal-derived humic compounds evaluated by the Ames test. Mutation Research 1996;369: 107-112. Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, Sabin CA, Timus A, Winter M, Baptista L, Johnson MA, Lee CA, Phillips AN, Janossy G. Increased numbers of primed activated CD8 + CD38 + CD45RO + T cells predict the decline of CD4 + T cells in HIV-1 -infected patients. AIDS 1996;10:827-834. Brandt H. Die Behandlung degenerativer Erkrakungen der Wirbelsaule und der Gelenke mit salizylierten Huminsaurebadern. Fortschr Med 1964;82: 110. Cloete TE, Swart H, Cronje IJ, Dekker J. Oxidized coal products as industrial bactericides. Third International Symposium on Gas, Oil, Coal and Environmental Biotechnology. 3-5 December 1990, New Orleans, Louisiana. Davies G. Properties and Functions of Humic Acids, Meeting Report. The Nucleus Febr. 1996, p 17. Eichelsdorfer D. Moor in der Heilkunde. In: Moor- und Torfkunde. Ed K Gottlich, Schweizerbart. Stuttgart, 1976. Gramsch H. Ein Beitrag zur Behandlung der Gastropathien. Med Monatsschr. 1961;15:658-687. Haanel BF. Facts about peat, Mines Branch Publ No 614, Can Dept Mines, Ottawa, 1924. Klocking R, Sprossig M, Wutzler P, Thiel KD, Helbig B. Antiviral wirksam Huminsaureahnliche Polymere, Z. Physiother. 1983;33:95-101. Lopez-Ferandez MF, Bianco-Lopes MJ, Castineira MP, Batlle J. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII. Am J Hematol 1992;40:20-27. Motohisa S, Yoshinori H, Shuzo K. Humic acids for treatment of skin disorders. In: C A 80, 1974, p 283 100222u. Patent Japan. Kokai 7392, 524. Reichert B. Huminsauren und ihre Derivate in der modernen Therapie. Dtsch Apoth 1966;18:204-206. Salz H. Salhumin-Gel, ein Lokaltherapeutikum mit hyperamisierender, entzundungshemmender und analgetischer Wirkung. Med Monatsschr 1974;28:548- 550. Sato T, Ose Y, Nagase H. Desmutagenic effect of humic acid. Mutation Research 1986;162: 173-178. Schneider J, Weis R, Manner C, Kary B, Werner A, Seubert BJ, Riede UN. Inhibition of HIV-1 in cell culture by synthetic humate analogues derived from hydroquinone: mechanism of inhibition. Virology 1996;218:389-395. Thiel KD, Klocking R, Schweizer H, Sprossig M. Untersuchungen in vitro zur antiviralen Aktivitat von Ammoniumhumat gegenϋber Herpes simplex-Virus Typ 1 und Typ 2, Zentralbl. Bakteriol, Parasiten kd, Infection skr Hyg Abt 1 1977;239:301- 321. Visser SA. Some biological effects of humic acids in the rat. Acta Biol Med Germ 1973;31:569-581. Visser SA. Surface active phenomena by humic substances of aquatic origin. Rev Fr Sci Eau 1982;1:285-295. Zsindely A, Hofmann R, Klocking R. Uber den Einfluss oral applizierter Huminsauren auf den Nukleinsaurestoffwechsel von Ascites-rumorzellen bei Mausen. Acta Bio. Debrecina 1971 ;9:71-77.

Claims: CLAIMS 1. A pharmaceutical composition comprising an oxihumic acid, salt, ester or derivative thereof as an active ingredient. 2. A pharmaceutical composition according to claim 1 wherein the oxihumic acid, salt, ester or derivative thereof has the following functional group analysis: Total acid groups: 3 - 13 meq/g; Carboxylic groups: 0.5-12 meq/g; and Phenolic groups: 0.5 - 9 meq/g. 3. A pharmaceutical composition according to claim 2 wherein the oxihumic acid, salt, ester or derivative thereof has the following functional group analysis: Total acid groups: 5.4 meq/g; Carboxylic groups: 2.2 meq/g; and Phenolic groups: 3.2 meq/g. 4. A pharmaceutical composition according to any one of the preceding claims wherein the composition is for oral administration. 5. An oxihumic acid, salt, ester or derivative thereof for use in the manufacture of a medicament for use in stimulating lymphocytes in a subject. 6. An oxihumic acid, salt, ester or derivative thereof of claim 5 wherein the lymphocytes are THI and TH2 lymphocytes. 7. An oxihumic acid, salt, ester or derivative thereof for use in the manufacture of a medicament for use in the treatment of viral or bacterial infections or both in a subject. 8. An oxihumic acid, salt, ester or derivative thereof for use in the manufacture of a medicament for use in the treatment of HIV infections or opportunistic diseases or both in a subject. 9. An oxihumic acid, salt, ester or derivative thereof for use in the manufacture of a medicament for use in the treatment of inflammation, pain or fever or combinations thereof in a subject. 10. An oxihumic acid, salt, ester or derivative thereof for use in the manufacture of a medicament for use in decreasing PGE2 secretion by stimulated lymphocytes in the treatment of inflammation in a subject. 11. An oxihumic acid, salt, ester or derivative thereof for use in the manufacture of a medicament for use in decreasing TNF secretion by stimulated lymphocytes in the treatment of inflammation in a subject. 12. An oxihumic acid, salt, ester or derivative thereof for use in the manufacture of a medicament for use in inhibiting expression of adhesion molecules on cell surfaces in the treatment of inflammation in a subject. 13. An oxihumic acid, salt, ester or derivative thereof of claim 12 wherein the adhesion molecules are CR3 molecules. 14. An oxihumic acid, salt, ester or derivative thereof for use in the manufacture of a medicament for use in inhibiting cancer growth in a subject. 15. An oxihumic acid, salt, ester or derivative thereof for use in the manufacture of a medicament for use in the treatment of a disease associated with a viral infection and a depressed immune system in a subject. 16. An oxihumic acid, salt, ester or derivative thereof of claim 15 wherein the disease is myalgic encephalitis. 17. An oxihumic acid, salt, ester or derivative thereof according to any one of the claims 5 to 16 wherein the medicament is for oral administration. 18. An oxihumic acid, salt, ester or derivative thereof according to any one of claims 5 to 17 wherein the subject is a human, animal or bird. 19. A method of stimulating lymphocytes in a subject which includes the steps of administering an oxihumic acid, salt, ester or derivative thereof to the subject. 20. A method of claim 19 wherein the lymphocytes stimulated are TH I and TH2 lymphocytes. 21. A method of treating viral or bacterial infections or both in a subject which includes the steps of administering an oxihumic acid, salt, ester or derivative thereof to the subject. 22. A method of treating HIV infections or opportunistic diseases or both in a subject which includes the steps of administering an oxihumic acid, salt, ester or derivative thereof to the subject. 23. A method of treating inflammation, pain or fever or combinations thereof in a subject which includes the steps of administering an oxihumic acid, salt, ester or derivative thereof to the subject. 24. A method of decreasing PGE2 secretion by stimulated lymphocytes in the treatment of inflammation in a subject which includes the steps of administering an oxihumic acid, salt, ester or derivative thereof to the subject. 25. A method of decreasing TNF secretion by stimulated lymphocytes in the treatment of inflammation in a subject which includes the steps of administering an oxihumic acid, salt, ester or derivative thereof to the subject. 26. A method of inhibiting expression of adhesion molecules on cell surfaces in the treatment of inflammation in a subject which includes the steps of administering an oxihumic acid, salt, ester or derivative thereof to the subject. 27. A method of claim 26 wherein the adhesion molecules are CR3 molecules. 28. A method of inhibiting cancer growth in a subject which includes the steps of administering an oxihumic acid, salt, ester or derivative thereof to the subject. 29. A method of treating a disease associated with a viral infection and a depressed immune system in a subject which includes the steps of administering an oxihumic acid, salt, ester or derivative thereof to the subject. 30. A method of claim 29 wherein the disease is myalgic encephalities. 31. A method according to any one of claims 19 to 30 wherein the administration is oral. 32. A method according to any one of claims 19 to 31 wherein the subject is a human, animal or bird.

Inventors: DEKKER JOHANNES, MEDLEN CONSTANCE ELIZABETH, DEKKER, JOHANNES, MEDLEN, CONSTANCE, ELIZABETH
Applicants: DEKKER JOHANNES, ENERKOM PTY LTD, MEDLEN CONSTANCE ELIZABETH, DEKKER, JOHANNES, ENERKOM (PROPRIETARY) LIMITED, MEDLEN, CONSTANCE, ELIZABETH
Application year: 1999
Main classification: A61K35
IPC codes: A61K35, A61K36